Administering DC-targeted constructs with tumor antigens(Trp1/gp100) into mice bearing aggressive B16–F10 melanomasimproved mouse outcomes when compared to free antigen, including suppressedtumor growth up to 58% at 16 days post tumor induction (P < 0.0001) and increased survival (P = 0.03).These studies demonstrate that harnessing DC-targeting anthrax proteinsfor cytosolic antigen delivery significantly enhances the immunogenicityand antitumor efficacy of cancer vaccines. The gene discussed is PMEL; the disease is cancer.